XML 49 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment information | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Segment information | Segment information We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below. Revenues Revenues were as follows (in millions):
| Years ended December 31,
| 2017 |  | 2016 |  | 2015
Product sales: |  |  |  |  |
ENBREL | $ | 5,433 |  |  | $ | 5,965 |  |  | $ | 5,364 |
Neulasta® | 4,534 |  |  | 4,648 |  |  | 4,715 |
Aranesp® | 2,053 |  |  | 2,093 |  |  | 1,951 |
Prolia® | 1,968 |  |  | 1,635 |  |  | 1,312 |
Sensipar®/Mimpara® | 1,718 |  |  | 1,582 |  |  | 1,415 |
XGEVA® | 1,575 |  |  | 1,529 |  |  | 1,405 |
EPOGEN® | 1,096 |  |  | 1,282 |  |  | 1,856 |
KYPROLIS® | 835 |  |  | 692 |  |  | 512 |
Vectibix® | 642 |  |  | 611 |  |  | 549 |
Nplate® | 642 |  |  | 584 |  |  | 525 |
NEUPOGEN® | 549 |  |  | 765 |  |  | 1,049 |
Repatha® | 319 |  |  | 141 |  |  | 10 |
BLINCYTO® | 175 |  |  | 115 |  |  | 77 |
Other | 256 |  |  | 250 |  |  | 204 |
Total product sales | 21,795 |  |  | 21,892 |  |  | 20,944 |
Other revenues | 1,054 |  |  | 1,099 |  |  | 718 |
Total revenues | $ | 22,849 |  |  | $ | 22,991 |  |  | $ | 21,662 |
Geographic information Outside the United States, we sell products principally in Europe. The geographic classification of product sales is based on the location of the customer. The geographic classification of all other revenues is based on the domicile of the entity from which the revenues were earned. Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment, net) was as follows (in millions):
| Years ended December 31,
| 2017 |  | 2016 |  | 2015
Revenues: |  |  |  |  |
United States | $ | 18,029 |  |  | $ | 18,326 |  |  | $ | 17,167 |
Rest of the world (ROW) | 4,820 |  |  | 4,665 |  |  | 4,495 |
Total revenues | $ | 22,849 |  |  | $ | 22,991 |  |  | $ | 21,662 |
| December 31,
| 2017 |  | 2016
Long-lived assets: |  |  |
United States | $ | 2,349 |  |  | $ | 2,328 |
Puerto Rico | 1,527 |  |  | 1,591 |
ROW | 1,113 |  |  | 1,042 |
Total long-lived assets | $ | 4,989 |  |  | $ | 4,961 |
Major customers In the United States, we sell primarily to pharmaceutical wholesale distributors that we utilize as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance. We had product sales to three customers each accounting for more than 10% of total revenues for each of the years ended December 31, 2017, 2016 and 2015. For the year ended December 31, 2017, on a combined basis, these customers accounted for 81% and 96% of total gross revenues and U.S. gross product sales, respectively, as noted in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2017 |  | 2016 |  | 2015
AmerisourceBergen Corporation: |  |  |  |  |
Gross product sales | $ | 10,742 |  |  | $ | 10,100 |  |  | $ | 10,038 |
% of total gross revenues | 31 | % |  | 31 | % |  | 34 | %
% of U.S. gross product sales | 37 | % |  | 38 | % |  | 42 | %
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 10,625 |  |  | $ | 9,710 |  |  | $ | 8,766 |
% of total gross revenues | 30 | % |  | 30 | % |  | 30 | %
% of U.S. gross product sales | 35 | % |  | 34 | % |  | 34 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 7,049 |  |  | $ | 6,520 |  |  | $ | 5,045 |
% of total gross revenues | 20 | % |  | 20 | % |  | 17 | %
% of U.S. gross product sales | 24 | % |  | 24 | % |  | 21 | %
As of December 31, 2017 and 2016, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 75% and 76%, respectively, of net trade receivables on a combined basis. As of December 31, 2017 and 2016, 14% and 21%, respectively, of trade receivables, net, were due from customers located outside the United States, primarily in Europe. Our total allowance for doubtful accounts as of December 31, 2017 and 2016 was not material.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration